Prevalence of Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic Adenocarcinoma (PAPAFA)

Centre Hospitalier Saint Joseph Saint Luc de Lyon

Status

Completed

Conditions

Prevalence of Pancreas Adenocarcinomas

Treatments

Procedure: Pancreatic MRI

Study type

Interventional

Funder types

Other

Identifiers

NCT02810730

0502198069

Details and patient eligibility

About

Pancreatic adenocarcinoma is the 4th leading cause of cancer in the USA. Its incidence is increasing both in France and in Europe, whereas all the other cancers are decreasing in Europe. Moreover, its seriousness is still high, with a mortality rate higher than the average incidence. The aim of PAPAFA study is to assess the prevalence of the pancreatic anomalies which can be revealed thanks to imaging, for patients having a 1st degree pancreatic adenocarcinoma familial history. This could allow detection of lesions which are less than 10 mm long, and improve the dark prognostic of this pathology.

Enrollment

200 patients

Sex

All

Ages

40+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

patients with a 1st degree familial history of pancreas adenocarcinoma
patients older than 40
patients whose life expectancy is > 3 months
inform and consent form signed
patient insured under the French social security system

Exclusion criteria

contraindication to the MRI (pace-maker, implanted metallic material, medical history of allergy to the contrast agent, end-stage renal failure, pregnancy, claustrophobia)
contraindication to anesthesia to do the echo endoscopy
1st degree family history of 2 pancreas adenocarinomas
medical history of allergy to benzylic alcool
contraindication to dimeglumine gadobenate
pregnant or breastfeeding woman, according to the questioning
subjets who don't have the legal capacity to consent